We can highlight the next thriving fund investment areas, such as Biopharma, Life Science. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight A-Mansia Biotech.
The important activity for fund was in 2018. The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The standard case for the fund is to invest in rounds with 5 partakers. Despite the the SRIW Life Sciences, startups are often financed by Wallonia Regional Government. The meaningful sponsors for the fund in investment in the same round are Seventure Partners, Pierre Drion, Nivelinvest.
Related Funds
| Fund Name | Location |
| Akoya Capital Partners | Chicago, Illinois, United States |
| Bedrock Ventures | Delhi, Delhi, India |
| Bling Capital | California, San Francisco, United States |
| CanopyBoulder | Boulder, Colorado, United States |
| CerraCap Ventures | California, Costa Mesa, United States |
| Craigie Capital | England, London, United Kingdom |
| Dai-ichi Kangyo Credit Cooperative | - |
| Encevo | Canton Esch-sur-Alzette, Esch-sur-Alzette, Luxembourg |
| Fueled | New York, New York, United States |
| Gateway | California, Oakland, United States |
| GCI Venture Partners | District of Columbia, United States, Washington |
| Gigafund | Austin, Texas, United States |
| NSW Treasury Corporation | - |
| Pivotal bioVenture Partners China | China, Shanghai |
| SeedToB Capital | Georgia, Suwanee, United States |
| Skywell Capital | Cyprus, Nicosia |
| Viola Partners | Herzliya, Israel, Tel Aviv |
| Virginia Catalyst | Richmond, United States, Virginia |
| W250 Venture Fund | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Novadip Biosciences | $28M | 03 Nov 2022 | Belgium, Walloon Brabant, Belgium | ||
Novadip Biosciences | $22M | 28 Oct 2021 | Belgium, Walloon Brabant, Belgium | ||
A-Mansia Biotech | $15M | 27 Apr 2018 | Belgium, Limburg |
– ExeVir from Ghent, Belgium develops single domain antibody therapies providing broad protection against viral infections.
– The company closed its Series A financing raising a total of US$50m.
– Led by Fund+, the round was also joined by VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest as well as several Belgian family offices.
– The company is using the funds to commence the global phase 1b/2 clinical trial of lead compound XVR011 and develop a VHH72-Fc sub-cutaneous formulation for Covid-19 in parallel and accelerate development of its pipeline beyond Covid-19 in infectious diseases.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Novadip Biosciences | $28M | 03 Nov 2022 | Belgium, Walloon Brabant, Belgium | ||
Novadip Biosciences | $22M | 28 Oct 2021 | Belgium, Walloon Brabant, Belgium | ||
A-Mansia Biotech | $15M | 27 Apr 2018 | Belgium, Limburg |
